There is more competition in play for Emgality from Lundbeck’s new intravenous ... in a clinic rather than by subcutaneous self-injection. Amgen reported $306 million from US sales of Aimovig ...
NICE has backed Emgality (galcanezumab) as a once-monthly injection to prevent migraine attacks in people with episodic or chronic migraine who suffer at least four days with a migraine headache ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback